US 12,421,213 B2
Benzamides of pyrazolylamino- pyrimidinyl derivatives, and compositions and methods thereof
Zhaokui Wan, Hangzhou (CN); Michael Lawrence Vazquez, Creve Coeur, MO (US); and Xiaodong Li, Hangzhou (CN)
Assigned to LYNK PHARMACEUTICALS CO. LTD., Hangzhou (CN)
Filed by LYNK PHARMACEUTICALS CO. LTD., Hangzhou (CN)
Filed on Mar. 1, 2022, as Appl. No. 17/684,030.
Application 17/684,030 is a continuation of application No. 17/278,553, filed on Mar. 22, 2021, abandoned.
Application 17/278,553 is a continuation in part of application No. PCT/CN2018/012116, filed on Dec. 14, 2018.
Prior Publication US 2023/0002362 A1, Jan. 5, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 403/12 (2006.01); C07D 401/14 (2006.01); C07D 403/14 (2006.01); C07D 405/14 (2006.01); C07D 471/08 (2006.01); C07D 493/08 (2006.01)
CPC C07D 403/12 (2013.01) [C07D 401/14 (2013.01); C07D 403/14 (2013.01); C07D 405/14 (2013.01); C07D 471/08 (2013.01); C07D 493/08 (2013.01)] 14 Claims
 
1. A method for treating a disease or disorder, comprising
administering to a subject in need thereof a pharmaceutical composition comprising a compound having the structural formula of (I):

OG Complex Work Unit Chemistry
wherein
X is CH;
Z1 is CH;
Z2 is N;
R1 is Cl;
R2 is a C1-C6 alkyl, cycloalkyl or heterocycloalkyl group optionally comprising one or more heteroatoms selected from N, O, and S, wherein the alkyl, cycloalkyl or heterocycloalkyl group is optionally substituted with one or more of halogen, OR′, NRR′, CN, CONRR′, NRCOR′ and C1-C6 alkyl, which is in turn optionally substituted with F, OR′ or NRR′;
R3 is H;
R4′ is H;
R4 is —CHR″—R5, wherein R″ is H or a C1-C6 alkyl and R5 is a CN, CF3 or OR′; and
each R and R′ is independently hydrogen or a C1-C12 unsubstituted or substituted alkyl group,
or a pharmaceutically acceptable salt or an isotope derivative thereof, wherein the disease or disorder is selected from the group consisting of inflammatory bowel disease, psoriasis, psoriatic arthritis, alopecia areata, eczema, vitiligo, atopic dermatitis, systemic lupus erythematosus, asthma, diabetic nephropathy, chronic myelogenous leukemia (CML), essential thrombocythemia (ET), polycythemia vera (PV), myelofibrosis (MF), breast cancer and ovarian cancer.